Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bevacizumab + infliximab
- Development stage
- Discontinued
- Lead developer
- Genentech
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravitreal
01
Overview
bevacizumab + infliximab is a combination therapy consisting of two monoclonal antibodies: bevacizumab, which targets vascular endothelial growth factor (VEGF), and infliximab, which targets tumor necrosis factor-alpha (TNF-α). This combination was investigated for the treatment of neovascular age-related macular degeneration (nAMD) to evaluate the potential synergistic effects of inhibiting both angiogenesis and inflammation. In clinical feasibility studies, the combination demonstrated efficacy in reducing macular thickness and leakage in patients with choroidal neovascularization. However, significant safety concerns were identified, including the development of cataracts in all phakic eyes and instances of intraocular inflammation (vitritis). Consequently, the combination is not recommended for clinical practice in this indication due to these adverse reactions.
- Brand names
- Avastin + Remicade
02
Targets
TNFA (Tumor necrosis factor alpha (soluble))VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on bevacizumab + infliximab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bevacizumab + infliximab.